top of page

HELP 4 HD INTERNATIONAL

Stand Up Speak Up 4 HD 🎉 Click Here

Search

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy

katie8288

Jun 23, 2022

0 min read

Recent Posts

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease Patients

Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer

Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

Comments

bottom of page